drugset / Trial / NCT01963715
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
Timeline
- Start
- 2013-10
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMGN289 | Unknown | — | Intravenous |
Indications
No indication recorded.